MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$1,882K
EPS
-$0.07
Unit: Thousand (K) dollars

Income Statement
2025-12-31
2024-12-31
Research and development - licenses acquired
-252
Net revenue
63,262 57,675
Cost of goods - (excluding amortization of acquired intangible assets)
20,924 20,879
Asset impairment
-3,692
Amortization of acquired intangible assets
4,258 3,424
Research and development
11,901 56,629
Loss recovery
-4,553
Selling, general and administrative
96,400 87,731
Total operating expenses
133,483 168,054
Loss from operations
-70,221 -110,379
Interest income
2,485 2,683
Interest expense and financing fee
10,106 13,527
Loss on common stock warrant liabilities
-398 -638
Gain from deconsolidation of subsidiary
27,127 -
Other income
17,578 1,318
Total other income (expense)
36,686 -10,164
Loss before income tax expense
-33,535 -120,543
Income tax expense (benefit)
-620 312
Net loss
-32,915 -120,855
Attributable to non-controlling interests
-39,730 -74,858
Net income (loss) attributable to fortress
6,815 -45,997
Preferred a dividends declared and paid and/or cumulated, and fortress' share of subsidiary deemed dividends
8,697 9,893
Net loss attributable to common stockholders
-1,882 -55,890
Basic EPS
-0.07 -2.69
Diluted EPS
-0.07 -2.69
Basic Average Shares
27,901,889 20,784,334
Diluted Average Shares
27,901,889 20,784,334
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Attributable tonon-controlling interests-$39,730K (46.93%↑ Y/Y)Net lossattributable to common...-$1,882K (96.63%↑ Y/Y)Net income (loss)attributable to fortress$6,815K (114.82%↑ Y/Y)Net loss-$32,915K (72.76%↑ Y/Y)Income tax expense(benefit)-$620K (-298.72%↓ Y/Y)Gain fromdeconsolidation of subsidiary$27,127K Other income$17,578K (1233.69%↑ Y/Y)Avenue TherapeuticsInc$1,404K (697.73%↑ Y/Y)Journey$619K (914.75%↑ Y/Y)Interest income$2,485K (-7.38%↓ Y/Y)Preferred a dividendsdeclared and paid and/or...$8,697K (-12.09%↓ Y/Y)Loss before incometax expense-$33,535K (72.18%↑ Y/Y)Total other income(expense)$36,686K (460.94%↑ Y/Y)Product revenue, net$61,239K (11.07%↑ Y/Y)Other revenue$2,023K (102.30%↑ Y/Y)Interest expense andfinancing fee$10,106K (-25.29%↓ Y/Y)Loss on common stockwarrant liabilities-$398K (37.62%↑ Y/Y)Loss from operations-$70,221K (36.38%↑ Y/Y)Net revenue$63,262K (9.69%↑ Y/Y)Total operatingexpenses$133,483K (-20.57%↓ Y/Y)Selling, general andadministrative$96,400K (9.88%↑ Y/Y)Cost of goods -(excluding amortization of...$20,924K (0.22%↑ Y/Y)Research and development$11,901K (-78.98%↓ Y/Y)Amortization of acquiredintangible assets$4,258K (24.36%↑ Y/Y)

Fortress Biotech, Inc. (FBIO)

Fortress Biotech, Inc. (FBIO)